Company: DNLI
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001714899-25-000105
Chunk: 99

Company: Denali Therapeutics Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 99
---
 Accruals and other current liabilities(6,477)2,321 Deferred research and development funding liability, less current portion16,733 — Net cash used in operating activities(131,468)(113,620)Investing activitiesPurchases of marketable securities(137,926)(834,157)Maturities and sales of marketable securities161,752 383,120 Purchases of property and equipment(5,078)(2,150)Net cash provided by (used in) investing activities18,748 (453,187)Financing activitiesProceeds from issuance of common stock and pre-funded warrants, net of issuance costs of $480— 499,253 Proceeds from exercise of awards under equity incentive plans595 1,022 Payments for finance lease right-of-use asset(4,357)— Net cash (used in) provided by financing activities(3,762)500,275 Net decrease in cash, cash equivalents and restricted cash(116,482)(66,532)Cash, cash equivalents and restricted cash at beginning of period176,535 128,681 Cash, cash equivalents and restricted cash at end of period$60,053 $62,149 Supplemental disclosures of cash flow informationRight-of-use asset obtained in exchange for new finance lease liabilities$2,876 $— Cash paid for finance lease interest$181 $— Equity consideration received in the divestiture of small molecule programs (Note 10)$— $15,000 Property and equipment purchases accrued but not yet paid$488 $1,947 Issuance costs incurred but not yet paid$— $394 

 See accompanying notes to unaudited condensed consolidated financial statements.

6

Denali Therapeutics Inc.

Notes to Condensed Consolidated Financial Statements 

(Unaudited)

1.    Significant Accounting Policies

Organization and Description of BusinessDenali Therapeutics Inc. ("Denali" or the “Company”) is a biopharmaceutical company, incorporated in Delaware, that discovers and develops therapeutics to defeat neurodegenerative diseases and lysosomal storage diseases. The Company is headquartered in South San Francisco, California.Basis of PresentationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of the Securities and Exchange